Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
tipifarnib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| tipifarnib (R115777) | DRUG | - |
Inclusion Criteria: * Refractory or relapsed Acute myeloid leukemia (AML) * Eastern Cooperative Oncology Group (ECOG) performance of 0-2 * any value of WBC * able to eat food and medication orally * females must use contraception and not be pregnant Exclusion Criteria: * .Not in another study wit...
Tipifarnib is an investigational small molecule being studied for the treatment of acute myeloid leukemia, a type of nonlymphocytic leukemia. It is being developed by Johnson & Johnson (JNJ) and is currently in Phase 2 clinical development.
Tipifarnib is a farnesyl transferase inhibitor. It works by inhibiting the enzyme farnesyl transferase, which is involved in the signaling pathways of certain proteins that can promote cancer cell growth.
Tipifarnib is being developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ.
Tipifarnib is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed.
Tipifarnib has been studied in a completed Phase 2 clinical trial with the identifier NCT00354146. This trial enrolled 252 patients with refractory or relapsed acute myeloid leukemia and was an uncontrolled, open-label study.
Yes, tipifarnib is also known as R115777. In clinical trials, it is sometimes referred to by this alternative name, which is used interchangeably with tipifarnib.